RNA therapy slows harmful heart remodeling after heart attack in clinical trial

AI Summary

A new clinical trial has demonstrated that RNA therapy can effectively slow harmful heart remodeling processes following a heart attack. This therapy targets microRNA-132, a key regulator involved in the detrimental growth of heart muscle cells during recovery.

Following an acute heart attack, pathological remodeling processes occur in the heart. One consequence is so-called left ventricular systolic dysfunction, in which the pumping function of the left ventricle is impaired. To compensate for this, the heart muscle enlarges excessively, thereby becoming further weakened. The key regulator of this harmful growth of heart muscle cells is microRNA-132 (miR-132).